A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor
Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
The primary objective of this phase I study is to evaluate the safety and potential efficacy
and to determine the recommended phase 2 dose (RP2D) of IBI315, a HER2/PD-1 bi-specific
antibody in patients with advanced solid tumors